During Monday’s Current trade, Shares of Cousins Properties Inc (NYSE:CUZ), gain 0.20% to $10.00.
Cousins Properties Incorporated (CUZ) declared that it will release second quarter earnings after the market closes on Tuesday, July 28, 2015. Cousins invites you to take part in its Second Quarter 2015 Conference Call Wednesday, July 29, 2015 at 11 a.m. (Eastern Time). The number to call for this teleconference is (877) 247-1056. A 14-day playback will start at 1:00 p.m. (Eastern Time) on Wednesday, July 29, 2015 and run through Thursday, August 13, 2015. To access the playback, please dial (877) 344-7529 and enter the passcode 10068744. In addition, the replay can be accessed on the Company’s website, www.cousinsproperties.com, through the “Q2 2015 Cousins Properties Incorporated Earnings Conference Call” link on the Investor Relations page.
Cousins Properties Incorporated, a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, in addition to performs certain real estate-related services in the United States. The company operates through four divisions: Office/Multi-Family, Retail, Industrial, and Land.
Shares of Lam Research Corporation (NASDAQ:LRCX), inclined 0.09% to $75.52, during its current trading session.
Lam Research Corp. (LRCX), a major global supplier of innovative wafer fabrication equipment and services to the semiconductor industry, declared it has shipped its 200th Kiyo® conductor etch module with proprietary Hydra® technology. By enabling multiple patterning inflections at advanced nodes, the product is rapidly gaining momentum with customers across industry segments. In memory, the installed base is growing as a result of implementation for advanced DRAM, planar NAND, and 3D NAND with shipments doubling in the past quarter. In logic, the product is positioned at all major foundries and manufacturers focused on multi-patterning-intensive FinFET technology. In addition, Lam’s Kiyo with Hydra technology was recently successful in expanding its applications base at the 10 nm node by greater than five-fold over the previous node at a leading U.S. logic manufacturer.
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing systems used in the fabrication of integrated circuits. The company provides thin film deposition products, counting SABRE Product Family for copper damascene manufacturing; ALTUS systems deposit conformal atomic layer films for tungsten metallization applications; VECTOR family of plasma-improved chemical vapor deposition systems for the deposition of ashable hardmasks, oxides, nitrides, carbides, and anti-reflective layers; SPEED high-density plasma-chemical vapor deposition products for applications in STI, pre-metal dielectrics, inter-layer dielectrics, inter-metal dielectrics, and passivation layers; and SOLA ultraviolet thermal processing product family for the treatment of back-end-of-line low-k dielectric films and front-end-of-line silicon nitride strained films. The company also offers plasma etch products that remove materials from the wafer to create the features and patterns of a device.
Sequenom, Inc. (NASDAQ:SQNM), during its Monday’s current trading session decreased -2.90% to $2.85.
Sequenom, Inc. (SQNM) a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today the upcoming launch of the MaterniT™ GENOME laboratory-developed test. This test is the first noninvasive prenatal test (NIPT) to provide karyotype-level insight into fetal chromosomal status prior to considering an invasive procedure. The MaterniT GENOME test adds genome-wide identification of chromosomal gains or losses greater than 7 megabases (Mb) in size to Sequenom Laboratories’ growing NIPT testing portfolio.
The MaterniT GENOME test builds upon the industry leading microdeletion performance demonstrated by Sequenom Laboratories with the MaterniT21 PLUS laboratory-developed test, which was recently highlighted in an article by Hume JH, et al, published in the peer-reviewed journal Prenatal Diagnosis. Data supporting the validation of the MaterniT GENOME test will be presented at the 19th International Conference on Prenatal Diagnosis and Treatment (sponsored by the International Society of Prenatal Diagnosis and Therapy - ISPD) in Washington D.C., taking place July 12-15, 2015. The MaterniT GENOME test will be accessible to physicians later this quarter.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
Finally, Northern Oil & Gas, Inc. (NYSEMKT:NOG), decreased -3.19%, to $4.86.
Northern Oil and Gas, Inc. (NOG) declared that it anticipates to release second quarter 2015 financial and operating results on Wednesday, August 5, 2015 after market close.
Additionally, the Company plans to host a conference call on Thursday, August 6, 2015 at 10:00 AM Central Time.
Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of oil and natural gas properties in the United States. It primarily holds interest in the Bakken and Three Forks formations in the Williston Basin of North Dakota and Montana.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
